Details

Autor(en) / Beteiligte

• Yano, Ryoichi
• Konno, Aya
• Watanabe, Kyohei
• Tsukamoto, Hitoshi
• Kayano, Yuichiro
• Ohnaka, Hiroaki
• Goto, Nobuyuki
• Nakamura, Toshiaki
• Masada, Mikio

Titel

Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials

Ist Teil von

• International journal of clinical oncology, 2013-02, Vol.18 (1), p.96-104

Ort / Verlag

Japan: Springer Japan

Erscheinungsjahr

2013

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• Background Ethnic differences in drug susceptibility and toxicity are a major concern, not only in drug development but also in the clinical setting. We review the toxicity profiles of docetaxel according to dose and ethnicity. Methods We analyzed phase II and III clinical trials that included a once-every-3-weeks single-agent docetaxel arm. Logistic regression analysis was applied to identify the significant variables affecting the reported incidence of docetaxel-induced severe neutropenia. Results Multivariate logistic regression analysis identified studies conducted in Asia [odds ratio (OR) 19.0; 95% confidence interval (95% CI) 3.64–99.0] and docetaxel dose (OR 1.08; 95% CI 1.03–1.13) as independent variables for the incidence of grade 3/4 neutropenia. Conclusions There is a significant difference in the incidence of docetaxel-induced severe neutropenia between Asian and non-Asian clinical studies. Physicians and pharmacists should consider ethnic diversity in docetaxel toxicity when interpreting the results of clinical trials.